sidsdoc

📚✨ A proud decade of academic contribution by the @pcrrticonic Group! Four landmark books shaping #PediatricNephrology & #CriticalCare worldwide: 1️⃣ Critical Care Pediatric Nephrology & Dialysis Protocols Handbook 2️⃣ Advances in Critical Care Pediatric Nephrology: #POCUS 3️⃣ Atlas of Radiology in Pediatric Kidney Disorders 4️⃣ Pediatric Solid Organ Transplantation Protocols Handbook 🌍 Strengthening global education, practice & collaboration! #PCRRT #ICONIC #KidneyCare #PedsNephrology #Transplant #pcrrticonic #pcrrtadvances #CriticalCare #criticalcarenephrology @rupeshrainamd @MignonMcCulloch @TBunchman @kalhasanksu @sumersethi #MedTwitter @pednephrol @IPNA_PedNeph @isn_india @asian_PNA @ASPNeph @medicosmcqs @DrDhruvchauhan @IptaPedsTx @StarzlT @Alanepe1 @valerie_luyckx @drshyambansal @MedEdMahan @ahusindia @catochita @deepti_bahl @CharuThakar @arvindcanchi @drkafeelkhan @JasmineNephro @drkeithsiau @luck_urine @edgarvlermamd @MushtaqBilalPhD @NephroP @ISBP_ @Narayansgpgims @theliverdoc @ifkf_wka @AnandhUrmila @Vasuragh @minnie_sarwal @DevarajanPrasad @DDD_Askenazi

When we were in MAMC, and throughout my journey in medical colleges in graduation & post graduation there was an unspoken rule that seniors took care of juniors, helping them adjust to the tough life of residency. Senior most always took pride in paying the bill. That was a way of making juniors feel taken care of. The spirit of medicine should always be supporting those who come after us. Let’s strive to be the bigger versions of ourselves and the support system our juniors deserve. 🙏🏻

Great conference

World Kidney Day 2026 IAP Program 📅 12 March 2026 ⏰ 3-5pm (India Time) *Via IAP DIGI App* (Preferred): IOS: apps.apple.com/in/app/iap-dig… Android: play.google.com/store/apps/det… IAP DIGI Web Version* 😗 digital.iapindia.org @IPNA_PedNeph @WomenNeph_india @iapindia @rupeshrainamd

World Kidney Day 2026 IAP Program 🎓 *Theme* Critical Care Pediatric Nephrology – Where We Are! 💬 Special Segment: Panel Discussion Nephrotic Syndrome 📅 12 March 2026 ⏰ Time: 3:00 PM – 5:00 PM (India Time) @DelhiIap @iapindia @IPNA_PedNeph @IptaPedsTx @rupeshrainamd @Alanepe1

@KailashPRao1 @IPNA_PedNeph @IptaPedsTx @rupeshrainamd Well, the suggestion depends on the immunosuppressants child is on. Of course, we encourage healthy eating habits with complete NO to street food, and avoiding Junk food!

@sidsdoc @IPNA_PedNeph @IptaPedsTx @rupeshrainamd Sir, what is your suggestion

A child with nephrotic syndrome brought handwritten “food list” today, asking what he can eat & avoid. While restrictions r never pleasant, guidance is a must to protect children from unhealthy diet & obesity epidemic #WorldObesityDay @IPNA_PedNeph @IptaPedsTx @rupeshrainamd

@kamaldshah @pcrrticonic @IPNA_PedNeph @IptaPedsTx @rupeshrainamd Filled sheet had a new column of ‘sometimes!’, ‘kabhi kabhi!’, ‘mummy banaye to!’, ‘ghar ka’

@sidsdoc @pcrrticonic @IPNA_PedNeph @IptaPedsTx @rupeshrainamd Can we see a pic of the filled in sheet Dr. Sethi? 😀

😊🙏🏻 Happy to share our recent work published in Clinical Kidney Journal (CKJ) European Renal Association (ERA) 🎉On “Artificial intelligence for predicting pediatric acute kidney injury: a systematic review and meta-analysis” @CKJsocial Congratulations to Prof. @rupeshrainamd and the entire team for leading this important work advancing AI-driven prediction in pediatric acute kidney injury. This study synthesizes current evidence on AI/ML models for early detection and risk stratification of AKI in hospitalized children—an area with significant clinical impact potential. 🔗 Read the full article: doi.org/10.1093/ckj/sf… Title “Artificial intelligence for predicting pediatric acute kidney injury: a systematic review and meta-analysis” Authors: Rupesh Raina, Parth Shirode, Raghav Shah, Aanya Chepyala, Abhishek Tibrewal, Sidharth Kumar Sethi, Wisit Cheungpasitporn 🔗 Read the full article: doi.org/10.1093/ckj/sf… As we continue to build, validate, and responsibly implement these tools, moving forward with AI in kidney care is truly exciting. #AI #Nephrology #KidneyCare

Thanks for all your leadership and guidance

Thank God—I published 24 papers in 2025, including two in The Lancet. Many thanks to all my colleagues and research teams I’ve had the pleasure to work with.@rupeshrainamd @sidsdoc @HaniTemsah_PICU @ksu_medicine @bandaraljafen

pubmed.ncbi.nlm.nih.gov/41663237/ pubmed.ncbi.nlm.nih.gov/36189502/ pubmed.ncbi.nlm.nih.gov/36189502/ pubmed.ncbi.nlm.nih.gov/41620553/ it is real STARZ for neonatal AKI score @sidsdoc @IPNA_PedNeph @IptaPedsTx @NKFCleveland @AkronChildrens @ASPNeph @adqi_p @drjosflynn @isn_india

RAMA: implementing Machine Learning to develop mortality risk prediction models for NICU patients with Acute Kidney Injury tandfonline.com/doi/full/10.10… @sidsdoc @NEOMEDedu @pcrrticonic @IPNA_PedNeph

tandfonline.com/doi/epdf/10.10… great AI Modeling for neonatal AKI @sidsdoc @pcrrticonic @Ped_Neph @IPNA_PedNeph @IptaPedsTx @AkronChildrens @NEOMEDedu @wisit661 @ESPNIC_Society @NeonatologyJC

This isn’t a random scientist who got lucky. Mariano Barbacid discovered the first human oncogene in 1982. He isolated H-RAS from bladder cancer cells and proved a single point mutation could trigger cancer. That finding launched the entire field of molecular oncology. KRAS mutations cause 90% of pancreatic cancers. For 43 years, oncologists called KRAS “undruggable” because the protein had no obvious binding pocket. Barbacid spent the last decade using genetically engineered mice to systematically test every node in the KRAS signaling pathway, looking for combinations that would work without killing the patient. The triple therapy blocks KRAS three ways at once: the main growth signal, the escape routes through EGFR and HER2, and the stress-response backup through STAT3. Cut the engine, seal the exits, disable the emergency system. Tumors vanished in mice and didn’t return for 200+ days after treatment stopped. Pancreatic cancer has a 13% five-year survival rate. 8% for the ductal adenocarcinoma type this therapy targets. Most patients live one year after diagnosis. The catch: this is preclinical. Human trials are 3+ years away. One of the drugs, RMC-6236, might get approved this year, but the full triple combination has regulatory hurdles. Still. The man who discovered human oncogenes in 1982 may have just figured out how to eliminate the cancer those genes cause. That’s a 43-year arc from first principles to potential cure. Science rarely works this clean.

A Spanish scientist have cured pancreatic cancer in mice. The most deadly cancer out there. People ignoring it and making fun of his birth defect. A cure in animal models is a huge step closer to a possible cancer treatment in humans. Thank you, Dr. Mariano Barbacid!

@simonmaechling Still, I would be optimistic and look forward to results and future trials. Indeed each and every therapy goes through these stages of trials.

Now that everyone is an expert on curing pancreatic cancer in mice, not rats - I want to add some context that goes beyond the headline. You will want to read this. Cancer is cured in mice all the time. Thousands of times. ~90% of those “cures” fail in humans. Why? Because mice are: Genetically simpler. Treated earlier. Short-lived. Not humans. Mice are a filter - not a finish line. Yes, this study matters. It comes from the Spanish National Cancer Research Centre. Yes, it’s pancreatic cancer - one of the deadliest there is. Yes, full tumor regression is impressive. But here’s what it actually means: “This approach is now good enough to risk years, trials, and millions of euros on.” Not: “Cancer is solved.” What happens next? More animal work. Toxicology. Phase I (safety). Phase II (maybe works). Phase III (beats standard care?). Maybe 8-10 years if everything goes right. The real damage isn’t failed drugs. It’s failed expectations. Every “cured cancer in mice” headline trains the public to believe: Cures are being hidden. Progress should be fast. Scientists are lying when reality hits. That’s how trust erodes. Bottom line: This is how real cancer progress looks. Messy. Slow. Risky. Incremental. Not miracles. Not conspiracies. Just science - doing the hard work.

I am tired of making pornstars and silly people famous. Let’s make him famous instead. The Spanish Dr. Mariano Barbacid has found the cure for the most common type of pancreatic cancer. He deserves the Nobel Price!

🚨⚡️A team of scientists in Spain has announced the discovery of a treatment for one of the most aggressive cancers ever (pancreatic cancer), which has a mortality rate of up to 97%. The Spanish scientist Mariano Barbacid and his team from the "Spanish National Cancer Research Centre" are currently the talk of the scientific community after they successfully achieved complete remission of advanced pancreatic tumors, which were previously considered hopeless cases. Clinical trials will begin soon, followed by approval for use of this treatment in humans.

Very good news! Dr. Mariano Barbacid and team successfully develops a promising new triple-combination therapy that completely and permanently eliminates pancreatic tumors. With such a successful preclinical study, we hope for the best in the coming clinical|human trials.

Wishing all the best to these researchers working on this aggressive disease with no cure.